Literature DB >> 16940805

Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response.

Saske Hoving1, Ann L B Seynhaeve, Sandra T van Tiel, Gisela aan de Wiel-Ambagtsheer, Ernst A de Bruijn, Alexander M M Eggermont, Timo L M ten Hagen.   

Abstract

Addition of high-dose tumor necrosis factor-alpha to melphalan-based isolated limb perfusion enhances anti-tumor effects impressively. Unfortunately, the mechanism of action of tumor necrosis factor-alpha is still not fully understood. Here, we investigated the effects of tumor necrosis factor-alpha on the tumor microenvironment and on secondary immunological events during and shortly after isolated limb perfusion in soft-tissue sarcoma-bearing rats. Already during isolated limb perfusion, softening of the tumor was observed. Co-administration of tumor necrosis factor-alpha in the isolated limb perfusion with melphalan induced a six-fold enhanced drug accumulation of melphalan in the tumor compared with isolated limb perfusion with melphalan alone. In addition, directly after perfusion with tumor necrosis factor-alpha plus melphalan, over a time-frame of 30 min, vascular destruction, erythrocyte extravasation and hemorrhage was detected. Interstitial fluid pressure and pH in the tumor, however, were not altered by tumor necrosis factor-alpha and no clear immune effects, cellular infiltration or cytokine expression were observed. Taken together, these results indicate that tumor necrosis factor-alpha induces rapid damage to the tumor vascular endothelial lining resulting in augmented drug accumulation. As other important parameters were not changed (e.g. interstitial fluid pressure and pH), we speculate that the tumor vascular changes, and concurrent hemorrhage and drug accumulation are the key explanations for the observed synergistic anti-tumor response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940805     DOI: 10.1097/01.cad.0000224450.54447.b3

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  11 in total

1.  Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours.

Authors:  G Spitaleri; R Berardi; C Pierantoni; T De Pas; C Noberasco; C Libbra; R González-Iglesias; L Giovannoni; A Tasciotti; D Neri; H D Menssen; F de Braud
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-17       Impact factor: 4.553

2.  Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.

Authors:  Hans D Menssen; Ulf Harnack; Ulrike Erben; Dario Neri; Burkhard Hirsch; Horst Dürkop
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-11       Impact factor: 4.553

3.  Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery.

Authors:  F Brunstein; J Rens; S T van Tiel; A M M Eggermont; T L M ten Hagen
Journal:  Br J Cancer       Date:  2006-11-14       Impact factor: 7.640

4.  TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature.

Authors:  L E Podleska; K Funk; L Umutlu; F Grabellus; G Taeger; H de Groot
Journal:  Br J Cancer       Date:  2015-07-14       Impact factor: 7.640

5.  Hemorrhage in mouse tumors induced by dodecaborate cluster lipids intended for boron neutron capture therapy.

Authors:  Tanja Schaffran; Nan Jiang; Markus Bergmann; Ekkehard Küstermann; Regine Süss; Rolf Schubert; Franz M Wagner; Doaa Awad; Detlef Gabel
Journal:  Int J Nanomedicine       Date:  2014-07-29

Review 6.  Unleashing endogenous TNF-alpha as a cancer immunotherapeutic.

Authors:  Steven F Josephs; Thomas E Ichim; Stephen M Prince; Santosh Kesari; Francesco M Marincola; Anton Rolando Escobedo; Amir Jafri
Journal:  J Transl Med       Date:  2018-08-31       Impact factor: 5.531

Review 7.  Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy.

Authors:  María Florencia Mercogliano; Sofía Bruni; Florencia Mauro; Patricia Virginia Elizalde; Roxana Schillaci
Journal:  Cancers (Basel)       Date:  2021-02-02       Impact factor: 6.639

8.  Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer.

Authors:  Xingxing Huang; Kun Ke; Weiwei Jin; Qianru Zhu; Qicong Zhu; Ruyi Mei; Ruonan Zhang; Shuxian Yu; Lan Shou; Xueni Sun; Jiao Feng; Ting Duan; Yiping Mou; Tian Xie; Qibiao Wu; Xinbing Sui
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

9.  Salivary Concentrations of Chemerin, α-Defensin 1, and TNF-α as Potential Biomarkers in the Early Diagnosis of Colorectal Cancer.

Authors:  Dariusz Waniczek; Elżbieta Świętochowska; Mirosław Śnietura; Paweł Kiczmer; Zbigniew Lorenc; Małgorzata Muc-Wierzgoń
Journal:  Metabolites       Date:  2022-07-28

Review 10.  Microbial Colonization and Inflammation as Potential Contributors to the Lack of Therapeutic Success in Oral Squamous Cell Carcinoma.

Authors:  Zoya Kurago; Jenni Loveless
Journal:  Front Oral Health       Date:  2021-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.